Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
Status:
Completed
Trial end date:
2010-05-14
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third
party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to
be conducted in conformance with Good Clinical Practices. This trial will investigate the
effects of single doses of preladenant and placebo on the dyskinesia and antiparkinsonian
actions of a levodopa infusion. The study will examine 10 mg ("low dose") or 100 mg ("high
dose") study drug, given as single, oral administrations in conjunction with intravenous (IV)
levodopa infusion and oral carbidopa.